StockSelector.com
  Research, Select, & Monitor Monday, June 25, 2018 3:13:38 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
BioMarin Pharmaceutical, Inc.$93.81($5.22)(5.27%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

BioMarin Pharmaceutical, Inc. has an overall rank of 973 out of 7142 stocks based on 11 positive rankings and 8 negative rankings.

Positive Rankings
SSValue
The StockSelector Value for BioMarin Pharmaceutical is $1,719.23. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, BioMarin Pharmaceutical is ranked 76.
PEGValue
BioMarin Pharmaceutical has a PEG Value of $382.24. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 285.98% in the next year. Among companies with a PEG Value above the current stock price, BioMarin Pharmaceutical is ranked 128.
Low vPut/Call
BioMarin Pharmaceutical has a low Put/Call ratio of 0.16 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, BioMarin Pharmaceutical is ranked 403.
10 Day Gain
BioMarin Pharmaceutical rank is 493
Low Put/Call
BioMarin Pharmaceutical has a low Put/Call ratio of 0.22 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, BioMarin Pharmaceutical is ranked 560.
Historic Revenue Growth
BioMarin Pharmaceutical rank is 646
Target Prices
The average analysts' target price is $101.00 for BioMarin Pharmaceutical using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, BioMarin Pharmaceutical is ranked 689.
Highest Cash Growth
BioMarin Pharmaceutical rank is 737
Estimated Revenue Growth
BioMarin Pharmaceutical rank is 741
90 Day Gain
BioMarin Pharmaceutical rank is 1078
Debt-to-Equity
BioMarin Pharmaceutical rank is 1409
Negative Rankings
Down Estimate Revision
During the past month, the consensus earnings estimate for the current year and next year have decreased by a combined (1.79%). Among companies that have had their estimates lowerec within the past month, BioMarin Pharmaceutical is ranked 255.
Overbought Stochastics
BioMarin Pharmaceutical rank is 395
Overbought RSI
The 14 Day Relative-Strength Index for BioMarin Pharmaceutical is 70.1. An RSI above 70 indicates the stock is overbought. Among companies with a high RSI, BioMarin Pharmaceutical is ranked 416.
Price-to-Sales
BioMarin Pharmaceutical rank is 445
Price-to-Book
BioMarin Pharmaceutical rank is 831
Negative Net Margin
BioMarin Pharmaceutical rank is 1123
Negative ROE
BioMarin Pharmaceutical rank is 1377
Negative ROA
BioMarin Pharmaceutical rank is 1592







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.